Shots:

• Elevar to receive $20M up front- ~$678M as milestones based on the company’s achievement regarding the product along with royalties on sales of Apealea globally excluding Nordics- Russia- and certain countries in Eastern Europe
• The agreement allows Elevar the right to sub-license Apealea to other partners in the EU. Elevar will be responsible for all regulatory activities in its territory- including the submission of the approval application to the FDA in the US
• Additionally- Elevar and Oasmia developed a joint development committee for Apealea to expand its approvals in Ovarian cancer globally while exploring its news indications. Oasmia will remain in sole control over and will continue to develop- its proprietary technology platform XR17- for use with active pharmaceutical ingredients other than paclitaxel

Source 1- Source 2 ­to­ read full press release/ article | Ref: Oasmia- Elevar | Image: Oasmia